10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
The US Food and Drug Administration has approved Eylea (aflibercept) Injection to treat all stages of diabetic retinopathy (DR), and thereby reduce the risk of blindness, marking the fifth indication for the drug in the USA. 14 May 2019
ElevateBio has closed a $150 million series A financing round and launched a full-spectrum cell and gene therapy incubator called ElevateBio BaseCamp, in Cambridge, USA. 14 May 2019
On May 10, 2019, the US Food and Drug Administration approved Cyramza (ramucirumab) from US pharma major Eli Lilly as a single agent for hepatocellular carcinoma (HCC; liver cancer) in patients who have an alpha fetoprotein (AFP) of ≥ 400ng/mL and have been previously treated with sorafenib (Nexavar). 13 May 2019
Despite the high-profile failure of an amyloid beta drug it was testing with Biogen earlier this year, Eisai is sticking to its promises not to give up in Alzheimer’s Disease (AD). 10 May 2019
While Waylivra (volanesorsen) has been snubbed by the US Food and Drug Administration, Europe’s regulator saw enough hopeful data to give the therapy a conditional approval in familial chylomicronemia syndrome (FCS). 10 May 2019
Sobi and Sanofi have presented further data to show that their drugs can provide perioperative hemostatic control across a wide spectrum of major and minor surgeries in patients of all ages with both severe hemophilia A and B. 10 May 2019
The US Food and Drug Administration has accepted for review a Biologics License Application (BLA) for a subcutaneous (SC) formulation of Entyvio (vedolizumab) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC). 10 May 2019
Gilead Sciences yesterday announced that it will donate Truvada (emtricitabine and tenofovir disoproxil fumarate tablets), for pre-exposure prophylaxis (PrEP) to the US Centers for Disease Control and Prevention (CDC) in support of national efforts to help prevent HIV and end the epidemic. 10 May 2019
Although approved in a number of cancer indications and bringing significant revenues for US pharma major Bristol-Myers Squibb’s, Opdivo (nivolumab) has seen another trial failure in the hard-to-treat brain cancer glioblastoma. 9 May 2019
Companies developing cell therapies for heart failure, compounds to treat obesity and peptide vaccines for cancer were among those that presented their pitches as part of a Japanese program to boost start-ups in the pharmaceutical sector. 9 May 2019
A first-of-its-kind trial of oral insulin being spearheaded by Israeli diabetes specialist Oramed Pharmaceuticals is now taking place at 37 research centers across the USA. 9 May 2019
An eight-month patient-led campaign to get the first ever treatment for early, inflammatory primary progressive multiple sclerosis (PPMS) paid for by the National Health Service (NHS) in England has ended in success. 9 May 2019
US biotech major Gilead Sciences has announced a strategic collaboration with Goldfinch Bio to discover and develop a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain rare kidney diseases. 9 May 2019
Europe’s largest privately-held biopharmaceutical company BioNTech has bought antibody assets and infrastructure from San Diego, USA-based MabVax Therapeutics. 9 May 2019
Pfizer has entered into a definitive agreement to acquire Swiss rare diseases focused biotech Therachon Holding, which has assets in development for the treatment of achondroplasia and short bowel syndrome (SBS). 9 May 2019
A team of researchers led by Harvard University scientists has improved the laboratory process of converting stem cells into insulin-producing beta cells, using biological and physical separation methods to enrich the proportion of beta cells in a sample. 8 May 2019
Even as Japanese pharma giant Takeda Pharmaceutical is consolidating its recent $62 billion acquisition of rare diseases specialist Shire, it has been entering a string of small licensing agreements. 8 May 2019
Following a positive opinion in March from the European Medicines Agency advisory committee, the European Commission (EC) has granted conditional marketing authorization for US pharma giant Pfizer’s Lorviqua (lorlatinib). 8 May 2019
Japanese pharma major Eisai knows from its own setbacks how challenging R&D in dementia is, but the company is not giving up and is now linking up with a UK charity to accelerate research. 8 May 2019
Swiss pharma giant Roche might be seeing competition start to erode sales of its big-selling cancer drugs, but sales of another of its products are heading in the opposite direction. 8 May 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024